New Delhi, Sep 7 (PTI) Drug firm Alembic Pharmaceuticals on Monday said its subsidiary has received tentative approval from the US health regulator for Treprostinil injection indicated for the treatment of pulmonary arterial hypertension.

The tentatively approved product is therapeutically equivalent to the reference listed drug product Remodulin injection of United Therapeutics Corp.

Also Read | Redmi 9 Prime & Redmi 9 to Go on Sale Today in India at 12 Noon via Amazon.in & Mi.com, Prices & Offers.

Alembic Global Holdings SA has received tentative approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Treprostinil Injection in the strengths of 20 mg/20 ml (1 mg/ml), 50 mg/20 ml (2.5 mg/ml), 100 mg/20 ml (5 mg/ml), and 200 mg/20 ml (10 mg/ml), multiple-dose vials, Alembic Pharmaceuticals said in a regulatory filing.

Quoting United Therapeutics Corporation's 2019 financial results, Alembic Pharma said Treprostinil injection has an estimated market size of USD 466.1 million for the 12 months ending December 2019.

Also Read | Xiaomi Mi TV Horizon Edition Launching Today in India at 12 Noon, Watch LIVE Streaming of Xiaomi's Launch Event.

Alembic now has a total of 131 ANDA approvals (113 final approvals and 18 tentative approvals) from the USFDA.

Shares of Alembic Pharmaceuticals were trading 1.55 per cent lower at Rs 913 apiece on the BSE.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)